Literature DB >> 16850056

Evolution of the National All Schedules Prescription Electronic Reporting Act (NASPER): a public law for balancing treatment of pain and drug abuse and diversion.

Laxmaiah Manchikanti1, Ed Whitfield, Frank Pallone.   

Abstract

In the United States, physicians are faced with two opposing dilemmas in the treatment of pain - the potential for drug abuse and diversion, and the possible undertreatment of pain. While controlled prescription drugs such as narcotic analgesics, anxiolytics, antidepressants, stimulants, and sedative-hypnotics, play a legitimate role in managing chronic pain and other conditions, the illicit use of prescribed medicines is increasing at epidemic proportions. Diversion and abuse of prescription drugs is costly in terms of addiction, overdose, death, and related criminal activities, but chronic pain carries significant economic, social, and health impact as well. The American Society of Interventional Pain Physicians (ASIPP), as the introducing organization, was joined by several physician and nurse practitioner organizations in support of the National All Schedules Prescription Electronic Reporting (NASPER) Act of 2005, legislation that not only will give physicians an information tool to aid in prescribing controlled substances but also will help identify illicit use and abuse. NASPER is the law that provides for the establishment of a controlled substances monitoring program in each state. The concept for NASPER originated with ASIPP and was modeled after the highly successful Kentucky All Schedules Prescription Electronic Reporting Program (KASPER). Legislation was introduced in the United States House of Representatives during three different Congresses, the 107th, 108th, and 109th, by Reps. Edward Whitfield (R-KY) and Frank Pallone (D-NJ). It was first introduced in the United States Senate in the 107th Congress by Sen. Tim Hutchinson (R-AK), and in the 108th and 109th by Sens. Jeff Sessions (R-AL) and Dick Durbin (D-IL), with multiple cosponsors in both chambers. NASPER passed the House on July 27, 2005, by voice vote and passed the Senate by unanimous consent on July 29, 2005. President George W. Bush signed NASPER on August 11, 2005, and it became Public Law 109-60. Implementation of NASPER will improve patient care and reduce abuse and diversion of prescription controlled substances.

Entities:  

Year:  2005        PMID: 16850056

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  8 in total

Review 1.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

Review 2.  Current State of Opioid Therapy and Abuse.

Authors:  Laxmaiah Manchikanti; Adam M Kaye; Alan D Kaye
Journal:  Curr Pain Headache Rep       Date:  2016-05

Review 3.  Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics.

Authors:  Jeanne M Manubay; Carrie Muchow; Maria A Sullivan
Journal:  Prim Care       Date:  2011-03       Impact factor: 2.907

Review 4.  Opioid Medications in the Management of Chronic Abdominal Pain.

Authors:  Dajie Wang
Journal:  Curr Pain Headache Rep       Date:  2017-08-08

5.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Authors:  Rebecca L Haffajee; Amy S B Bohnert; Pooja A Lagisetty
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043

6.  User Experiences of Prescription and Over-The-Counter Drug Abuse in Aden City, Yemen.

Authors:  Ebtesam A Abood; Jenny Scott; Mayyada Wazaify
Journal:  Pharmacy (Basel)       Date:  2018-09-13

7.  Prescription history of emergency department patients prescribed opioids.

Authors:  Jason A Hoppe; John Houghland; Michael Yaron; Kennon Heard
Journal:  West J Emerg Med       Date:  2013-05

8.  Estimating the prevalence of opioid diversion by "doctor shoppers" in the United States.

Authors:  Douglas C McDonald; Kenneth E Carlson
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.